Funding a pull incentive for antibiotic R&D in the United States would be more attractive to our representatives in Congress if we required that all manufacturing and supply chains for the beneficiary product be physically located in this country. Dr. David Shlaes (pictured), ACSH advisor and infectious disease expert, explains.
Funding a pull incentive for antibiotic R&D in the United States would be more attractive to our representatives in Congress if we required that all manufacturing and supply chains for the beneficiary product be physically located in this country. Dr. David Shlaes (pictured), ACSH advisor and infectious disease expert, explains.